Literature DB >> 12646771

Levetiracetam control of myoclonus in a patient with Creutzfeldt-Jakob disease.

Daniele Imperiale1, Simona Bortolotto, Anna Cucatto, Paola Schiffer, Daniela Cassano, Carlo Buffa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12646771     DOI： 10.1159/000069083

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


× No keyword cloud information.
  4 in total

Review 1.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

Review 2.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial.

Authors:  John Collinge; Michele Gorham; Fleur Hudson; Angus Kennedy; Geraldine Keogh; Suvankar Pal; Martin Rossor; Peter Rudge; Durre Siddique; Moira Spyer; Dafydd Thomas; Sarah Walker; Tom Webb; Steve Wroe; Janet Darbyshire
Journal:  Lancet Neurol       Date:  2009-03-09       Impact factor: 44.182

4.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.